The effect of two different regimens of hormone replacement therapy on coagulation and fibrinolysis was measured in 30 women taking Tibolone (Livial®) and 30 taking oestradiol valerate, sequentially combined with cyproterone acetate (Climen®). Blood samples were taken before the beginning of the medication, then six and twelve months afterwards. The Livial® group showed a rise of fibrinolytic activity äs measured by the a 2 -antiplasmin-plasmin complexes. Tissue plasminogen activator antigen and plasminogen activator inhibitor-1 decreased simultaneously. No effect was seen in the coagulation variables. In the Climen® group no significant alterations were noticed, either in the coagulation or in the fibrinolysis variables. In the direct comparison of both substances only factor VII appeared to be significantly higher in the Climen® group after six months and one year of treatinent.
Introduction
Hormonal replacement therapy has atträcted increasing interest in recent decades. It is now used by a substantial number of women to overcpme the various complaints of the menopause. In cases of an intact uterus, preparations are üsed in which the oestrogen component is either sequentially or continuously combined with a progestagen to prevent pharmaceütically induced endometrial hyperplasia and/or carcinöma (l, 2). Öestrogens have a vasodilatatory effect and influence the serum lipid coiicentrations favpuräbly (3) (4) (5) . Because lipids and haemostasis are linked (6) (7) (8) (9) , it is of interest to study the haemostatic effects of hormonal replaeement therapy. Öestrogens have been reported to enhance the plasma concentrations of several coagulation factors (fibrinogen, FII, VII, VHI:c, IX, X and XII) and the fibrinolysis factor plasminogen (10-13), whereas antithrombin III Was shown to be diminished (12, 14) ,
The progestagens administered in hormonal replacement therapy are either nortestosterone or progesterone derivates. The effect of progestagens on serum 'lipid concentrations caii be summarized äs an increase in total cholesterol and LDL-cholesterol, and a decrease in HDLcholesterol and triacylglycerols (15) , whereas progesterone derivatives appear to have no effect on these quantities. Effects on haemostasis are not well documented. Both an increase and decrease of fibrinogen have been described during the normal cycle (16, 17) . In general, however, a significant influence on the haemostatic system is not to be expected.
In this study the effect of two different regimens on the haemostatic profile was measured. Tibolone (Livial®), a synthetic steroid with oestrogenic, progestogenic and androgenic-anabolic properties, was given in a dose of 2.5 mg däily. This regimen was compared with the administration of 2 mg oestradiol valerate, which is immediately metabolized to the natural human oestrogen, oestradiol, and combined in the last 10 days of the cycle with l mg cyproterone acetate (Climen®).
Cyproterone acetate is a 17-hydroxyprogesterone derivative with progestogenic and anti-androgenic properties. Long-term cyclic treatment with cyproterone ace- täte given in the mentioned dose has no effect on the lipid metabolism (18) . Livial® is known to lower fibrinogen and factors VII and VIII (19, 20) , and to increase antithrombin III (21); enhanced fibrinolytic activity has been reported (19, 20) . In the present study the haemostatic effects of Livial® and Climeri® were compared. The essential difference between the two preparations is the presence and absence, respectively, of androgenic-anabolic properties.
Methods

Coagulation measurements
Fibrinogen was measured with a clotting assay (Merz and Dade) according to the method of Clauss, by means of a Schnittger & Gross coagulometer. F VII concentrations were assessed with an amidolytic test kit of Kabi Vitrum Diagnostica (Mölndal, Sweden). The prothrombin fragment l + 2 test was determined with an ELISA test kit (Behring Corporation, Marburg, Germariy). For the 'thrombin-antithrombin determination an ELISA test kit (Behring Corporation, Marburg, Germany) was used.
Fibrinolysis measurements
The D-dimer fibrin degradation products were measured by means of the FbDP test (Organen Technika, Boxtel, The Netherlands). The FbDP is a specific ELISA test fpr the determination of degradation products of cross-lmked fibrin only, and not of fibrinogen. For tissue plasminogen activator antigen and plasminogen activator inhibitor-1, ELISA test kits from Innogenetics (Antwe , Belgium) were used. The a^-antiplasmin-plasmin complex determinations were from Behring Corporation (Marburg, Germany).
Samples
Blood samples were drawn in citrate^containing plastic tubes after fasting ovemight between 8.30 and 9.30 a. m. and a resting period of 20 min before venipuncture. Alcohbl was not allowed the previous day. The analysis was conducted in citrated plasma prepared by centrifugation of nine volumes freshly collected blood with one volume trisodium citrate (0.11 mol/1) for 10 min (1600g) at 25 ?C. The plasma was stored at -70 °C in plastic tubes and thawed with tap water of 37 P C for 5 min before seriai analysis. .
Triäl design
Sixty healthy women with menopausal complaints, in the age groüp of 45-55, and between l -5 years after the menopause were admitted to an open randomized, comparative clinical trial over 12 treatment cycles. Their body weight was within Standard weight ± 10% (22) . Women with a history of drugs, smoking more than 10 cigarettes per day and/or drinking more than 40 ml of alcohol O per day were excluded frorn the study. They took no preparations which might influence lipids. Two menopausal centres participated aiid each centre included 30 women. Randbmization was conducted in blocks of 30. Each group used either Livial^ or Climen® con-tinuously for 12 monlhs. Livial® (Tiboione) was given in a dosage of 2.5 mg daily, without a tablet-free interval. The Climen® regimen consisted of 21 tablets containing 2 mg of oestradiol valerate with the last 10 tables containing additionally l mg cyproterone acetate and a 7-day tablet-free interval between every cycle. Medication was taken at about the same time in the evening. Blood samples were taken before the Start of the medication and between cycle days 18-21 of treatment cycles 6 and 12.
Statistics
The significance of the differences was assessed by the Mann-Whitney U test (level of significance p = 0.05).
The significance of the trends of the various analytes during the two treatment options was computed by the Kruskal-Wallis test (significance level p = 0.05).
Results
In Tissue plasminogen activator concentrations were significantly lower in the Livial® than in the Climen® group both after six months and after one year of treatment. Parallel behaviour was seen for plasminogen activator inhibitor-1 at the same stages of medication. The Livial® group showed higher values for a 2 -antiplasminplasmin complex after six and twelve months of treatment. The various coagulation and fibrinolysis quantities during Livial® and Climen® treatment were compared (at Start, after 6 and 12 months), using the KruskalWallis test. In the coagulation series, no trend was found in the course of one year of treatment with Climen®. With Livial® there were significant decreasing trends for tissue plasminogen activator (p = 0.01) and plasTab. 
Discussion
Coagulation and fibrinolysis were studied during a one year treatment of postmenopausal women with Livial® or Climen®, to investigate the influence of this medication on the haemostatic profile, and to establish potential differences in coagulation and fibrinolysis at Start and after six and twelve months of treatment. The two substances differ considerably in their chemical composition and pharmacological mechanisms. As androgenicanabolic substances are known to influence the fibrinolytic System, it might be expected that the administration of Livial®, which has an androgen-anabolic con> ponent, would give rise to changes in the concentrations of fibrinolysis markers (23) (24) (25) . This is confirmed by the changes in the fibrinolysis markers, tissue plasminogen activator, plasminogen activator inhibitor-1 and 012-antiplasmin-plasmin complex and the consistency of the coagulation quantities. During the Climeii® medication no influence on the studied coagulation and fibrinolysis markers was found. Evaluation of the results of both regimens confirms therefore the indifferent behaviour of Climen® in this respect. Livial® medication induced an enhancement of a 2 -antiplasmin-plasmin complex, which is indicative of an activation of the fibrinolysis System.
In general this effect might be considered to be advantageous. It is in line with previous studies (19, 20) which also reported a Stimulation of the fibrinolysis by Livial®, although less sensitive methods were used (19, 20) . Earlier studies, indicating that Livial® lowers the level of factor VII and of fibrinogen, were not confirmed. It could only be demonstrated that at the two stages of treatment the factor VII concentrations were lower in the Livial® group thän in the Climen® group.
In conclusion, both medications are indifferent to the coagulation System. Climen® is indifferent to the fibrinolysis System, whereas the Livial® regimen gave rise to a stimulated fibrinolytic activity, of which the clinical significance is still unclear.
